Bone and joint infections caused by Clostridium perfringens: a case series.
Adult
Aged
Aged, 80 and over
Anti-Bacterial Agents
/ therapeutic use
Bone Diseases
/ drug therapy
Clindamycin
/ therapeutic use
Clostridium Infections
/ drug therapy
Clostridium perfringens
/ drug effects
Female
Humans
Joint Diseases
/ drug therapy
Male
Microbial Sensitivity Tests
Middle Aged
Rifampin
/ therapeutic use
Bone infection
Clindamycin-rifampicin
Clostridium perfringens
Metronidazole
Journal
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
ISSN: 1435-4373
Titre abrégé: Eur J Clin Microbiol Infect Dis
Pays: Germany
ID NLM: 8804297
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
30
11
2020
accepted:
11
03
2021
pubmed:
17
3
2021
medline:
28
12
2021
entrez:
16
3
2021
Statut:
ppublish
Résumé
The objective of this study was to evaluate antimicrobial therapy outcomes of bone and joint infections (BJI) caused by Clostridium perfringens. We investigated remission of symptoms and the absence of relapse or reinfection during follow-up. Among the 8 patients with C. perfringens BJI, the type of infection was early prosthesis infection (n = 2), osteosynthetic device infection (n = 4), and chronic osteomyeletis (n = 2). Clindamycin-rifampicin combination was given in 4 cases and metronidazole in 4 cases. The overall success rate was 87.5%. Among the 7 patients who completed antibiotic treatment, the success rate was 100%. The clindamycin-rifampicin combination appeared to be effective in patients with C. perfringens BJI.
Identifiants
pubmed: 33723737
doi: 10.1007/s10096-021-04225-2
pii: 10.1007/s10096-021-04225-2
doi:
Substances chimiques
Anti-Bacterial Agents
0
Clindamycin
3U02EL437C
Rifampin
VJT6J7R4TR
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2221-2225Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Kiu R, Hall LJ (2018) An update on the human and animal enteric pathogen Clostridium perfringens. Emerg Microbes Infect 7:1–15
doi: 10.1038/s41426-018-0144-8
Brook I (2016) Spectrum and treatment of anaerobic infections. J Infect Chemother 22:1–13
doi: 10.1016/j.jiac.2015.10.010
Gredlein CM, Silverman ML, Downey MS (2000) Polymicrobial septic arthritis due to clostridium species: case report and review. Clin Infect Dis 30:590–594
doi: 10.1086/313686
Lotte R, Popoff MR, Degand N, Lotte L, Bouvet P, Baudin G et al (2014) Lumbar discitis caused by clostridium perfringens. J Clin Microbiol 52:3813–3815
doi: 10.1128/JCM.00983-14
Rush JH (1976) Clostridial infection in total hip joint replacement: a report of two cases. ANZ J Surg 46:45–48
doi: 10.1111/j.1445-2197.1976.tb03192.x
Shah NB, Tande AJ, Patel R, Berbari EF (2015) Anaerobic prosthetic joint infection. Anaerobe 36:1–8
doi: 10.1016/j.anaerobe.2015.08.003
SOCIETE FRANCAISE DE MICROBIOLOGIE. Comité de l’antibiogramme de la Société Française de Microbiologie- Recommandations 2019 V.2.0 Mai
CASFM / EUCAST V2.0 Mai 2019. https://www.sfm-microbiologie.org/2019/05/06/casfm-eucast-2019-v2/
Rutter WC, Burgess DS (2018) Incidence of acute kidney injury among patients treated with piperacillin-tazobactam or meropenem in combination with vancomycin. Antimicrob Agents Chemother 62:e00264–18, /aac/62/7/e00264–18.atom
Stevens DL, Maier KA, Mitten JE (1987) Effect of antibiotics on toxin production and viability of clostridium perfringens. Antimicrob Agents Chemother 31:213–218
doi: 10.1128/AAC.31.2.213
Société de Pathologie Infectieuse de Langue Française (SPILF), Collège des Universitaires de Maladies Infectieuses et Tropicales (CMIT), Groupe de Pathologie Infectieuse Pédiatrique (GPIP), Société Française d’Anesthésie et de Réanimation (SFAR), Société Française de Chirurgie Orthopédique et Traumatologique (SOFCOT), Société Française d’Hygiène Hospitalière (SFHH), et al. Recommendations for clinical practice. Osteo-articular infection therapy according to materials used (prosthesis, implants, osteosynthesis). Med Mal Infect 2009; 39:745–774
Stroud G, Vandiver JW (2020) Clostridium perfringens as an unusual cause of a prosthetic joint infection following total knee arthroplasty. IDCases 20:e00789
doi: 10.1016/j.idcr.2020.e00789
Fauser DJ, Zuckerman JD (1988) Clostridial septic arthritis: case report and review of the literature. Arthritis Rheum 31:295–298
doi: 10.1002/art.1780310221
Thabit AK, Fatani DF, Bamakhrama MS, Barnawi OA, Basudan LO, Alhejaili SF (2019) Antibiotic penetration into bone and joints: an updated review. Int J Infect Dis 81:128–136
doi: 10.1016/j.ijid.2019.02.005
Schilcher K, Andreoni F, Dengler Haunreiter V, Seidl K, Hasse B, Zinkernagel AS (2016) Modulation of Staphylococcus aureus biofilm matrix by subinhibitory concentrations of clindamycin. Antimicrob Agents Chemother 60:5957–5967
doi: 10.1128/AAC.00463-16
Kim B-N, Kim ES, Oh M-D (2014) Oral antibiotic treatment of staphylococcal bone and joint infections in adults. J Antimicrob Chemother 69:309–322
doi: 10.1093/jac/dkt374
Bonnaire A, Vernet-Garnier V, Lebrun D, Bajolet O, Bonnet M, Hentzien M et al (2021) Clindamycin combination treatment for the treatment of bone and joint infections caused by clindamycin-susceptible, erythromycin-resistant Staphylococcus spp. Diagn Microbiol Infect Dis 99:115225
doi: 10.1016/j.diagmicrobio.2020.115225
Bernard A, Kermarrec G, Parize P, Caruba T, Bouvet A, Mainardi J-L et al (2015) Dramatic reduction of clindamycin serum concentration in staphylococcal osteoarticular infection patients treated with the oral clindamycin-rifampicin combination. J Inf Secur 71:200–206
Goolsby TA, Jakeman B, Gaynes RP (2018) Clinical relevance of metronidazole and peripheral neuropathy: a systematic review of the literature. Int J Antimicrob Agents 51:319–325
doi: 10.1016/j.ijantimicag.2017.08.033
Kuriyama A, Jackson JL, Doi A, Kamiya T (2011) Metronidazole-induced central nervous system toxicity: a systematic review. Clin Neuropharmacol 34:241–247
doi: 10.1097/WNF.0b013e3182334b35
Hernández Ceruelos A, Romero-Quezada LC, Ruvalcaba Ledezma JC, López CL (2019) Therapeutic uses of metronidazole and its side effects: an update. Eur Rev Med Pharmacol Sci 23:397–401
pubmed: 30657582